Select a community
MS
Find out more about the PatientsLikeMe
MS Community
Home > Community Treatment Reports > Nuvigil Treatment Report
What is Nuvigil?

Nuvigil™ is a brand name for armodafinil, a stimulant that is used to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy and shift work sleep disorder; and as adjunctive therapy for obstructive sleep apnea/hypopnea syndrome.

Side Effects

Side effects as an overall problem

Severe
4 40%
Moderate
3 30%
Mild
1 10%
None
2 20%

Most commonly reported side effects

increased heart rate
5 50%
Inability to sleep
4 40%
Decreased appetite
3 30%
Sleeplessness
2 20%
Anxiety
2 20%
behavior changes
1 10%
  • Mild
  • Moderate
  • Severe

Dosages

  150mg as needed 1 g daily 1 mcg daily 1 mg daily 75 mg daily 100 mg daily 150 mg daily 250 mg daily
  6 Number of Patients: 6 1 Number of Patients: 1 1 Number of Patients: 1 4 Number of Patients: 4 2 Number of Patients: 2 1 Number of Patients: 1 20 Number of Patients: 20 7 Number of Patients: 7  

Stop Reasons

Why Patients Stopped Taking Nuvigil (multiple reasons could be selected)
Reason # Patients Percentage of patients
Other
5 50% Other: 50%
Expense
2 20% Expense: 20%
Did not seem to work
1 10% Did not seem to work: 10%
Side effects too severe
1 10% Side effects too severe: 10%
Change in health plan coverage
1 10% Change in health plan coverage: 10%

See all 10 patients who’ve stopped taking Nuvigil

Duration See details about how long patients take this treatment ▼

Currently Taking Nuvigil

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
5
20
16
0
1
0

Stopped Taking Nuvigil

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
5
3
2
0
0
0

Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Always
5 50%
Usually
2 20%
Sometimes
3 30%
Never
0 0%

Burden

Difficulty being on treatment

Very
1 10%
Somewhat
0 0%
A little
1 10%
Not at all
8 80%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
1 10%
$25-49
1 10%
< $25
4 40%

Report created on November 22, 2009.